Wang Yanhong, Zhang Long, Tian Jianhui, Luo Bin, Yao Jialiang, Yang Yun
Clinical Oncology Center, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China.
Institute of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Comb Chem High Throughput Screen. 2024 Jun 6. doi: 10.2174/0113862073298525240522104104.
Hepatocellular carcinoma (HCC) is a highly aggressive neoplasm that usually originates from liver cells and is one of the most common malignancies worldwide. To improve the survival rate of HCC patients, specific prognostic markers are essential to guide HCC therapy. CEP55 is a microtubule-bundling protein involved in critical cell functions, including cell growth, transformation, and cytokinesis.
This study examined gene alterations in HCC tumor tissues through comprehensive analysis, aiming to elucidate their contribution to disease development.
Bioinformatics tools were employed to investigate the expression, genetic variations, prognostic significance, and clinicopathological relevance of CEP55 across GEO and TCGA datasets. We further explored gene alterations, DNA methylation levels, and immune infiltration of CEP55. To elucidate the potential molecular mechanisms involved, GO and KEGG analysis was performed. Finally, RT-qPCR was also performed on a number of normal and tumoral cell lines in vitro, which demonstrated that the expression of the CEP55 was significantly higher in the tumor cell lines.
We observed that CEP55 was upregulated in 16 cancers compared to corresponding normal tissues. CEP55 was found to be related to T stages, pathologic stages, histologic grade, and levels of AFP. K-M analysis demonstrated that CEP55 expression was associated with a worse outcome. ROC curve analysis showed that CEP55 expression accurately distinguished HCC from normal tissue (AUC = 0.954). The area under 1-,3- and 5-year survival ROCs were above 0.6. The HSPA4 genetic alterations in HCC were 0.8%. Among the 15 DNA methylation CpG sites, 6 were related to the prognosis of HCC. HSPA4 was positively related to immune cell infiltration and immune checkpoints in HCC. The KEGG pathway analysis indicated that CEP55 was associated with the cell cycle and presented together with CDK1. HCC cell lines were demonstrated to express high levels of CEP55 compared to normal cells.
As a result of bioinformatic analyses and RT-qPCR validation in HCC, CEP55 increased in HCC tissues and was associated with the stage of the disease and survival rate.
肝细胞癌(HCC)是一种侵袭性很强的肿瘤,通常起源于肝细胞,是全球最常见的恶性肿瘤之一。为提高HCC患者的生存率,特定的预后标志物对于指导HCC治疗至关重要。CEP55是一种微管捆绑蛋白,参与关键的细胞功能,包括细胞生长、转化和胞质分裂。
本研究通过综合分析检测HCC肿瘤组织中的基因改变,旨在阐明它们对疾病发展的作用。
利用生物信息学工具研究CEP55在GEO和TCGA数据集中的表达、基因变异、预后意义及临床病理相关性。我们进一步探究了CEP55的基因改变、DNA甲基化水平和免疫浸润情况。为阐明其中潜在的分子机制,进行了GO和KEGG分析。最后,还对一些正常和肿瘤细胞系进行了体外RT-qPCR检测,结果表明CEP55在肿瘤细胞系中的表达明显更高。
我们观察到与相应正常组织相比,CEP55在16种癌症中表达上调。发现CEP55与T分期、病理分期、组织学分级和甲胎蛋白水平相关。K-M分析表明CEP55表达与较差的预后相关。ROC曲线分析显示,CEP55表达能准确区分HCC与正常组织(AUC = 0.954)。1年、3年和5年生存ROC曲线下面积均大于0.6。HCC中HSPA4基因改变率为0.8%。在15个DNA甲基化CpG位点中,6个与HCC的预后相关。HSPA4与HCC中的免疫细胞浸润和免疫检查点呈正相关。KEGG通路分析表明,CEP55与细胞周期相关,并与CDK1共同呈现。与正常细胞相比,HCC细胞系中CEP55表达水平较高。
通过对HCC进行生物信息学分析和RT-qPCR验证,结果表明CEP55在HCC组织中表达增加,且与疾病分期和生存率相关。